Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Med Chem. 2014 Oct 6;85:255-67. doi: 10.1016/j.ejmech.2014.07.100. Epub 2014 Jul 29.

Synthesis, biological evaluation and 3D-QSAR study of hydrazide, semicarbazide and thiosemicarbazide derivatives of 4-(adamantan-1-yl)quinoline as anti-tuberculosis agents.

Author information

  • 1Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, S. A. S. Nagar, Punjab 160 062, India.
  • 2Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, Sector 67, S. A. S. Nagar, Punjab 160 062, India.
  • 3Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, S. A. S. Nagar, Punjab 160 062, India. Electronic address: rahuljain@niper.ac.in.

Abstract

We report synthesis, anti-tuberculosis activity and 3D-QSAR study of forty nine hydrazide, semicarbazide and thiosemicarbazide derivatives of 4-(adamantan-1-yl)quinoline. The most potent compounds upon evaluation for anti-tuberculosis activity exhibited MIC99 of 3.125 μg/mL against Mycobacterium tuberculosis H37Rv strain. We applied the in silico technique of 3D-QSAR to study structure activity relationship of the synthesized compounds. The developed CoMFA model exhibited excellent r(2)ncv of 0.971, and r(2)cv of 0.543. The predicted r(2)pred of 0.883 showed that the predicted values were in good agreement with the experimental values. Further, the contour map analysis, suggested that the sterically bulky and electronegative substitutions at the para position of the phenyl ring are favorable for anti-tuberculosis activity.

Copyright © 2014 Elsevier Masson SAS. All rights reserved.

KEYWORDS:

CoMFA; Hydrazide; Quinolines; Semicarbazide; Thiosemicarbazide; Tuberculosis

PMID:
25089809
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk